DRUG MRZ-112 - Phast 1B, Multicenter, Open-Label Study of Marizomib Combined with Temozolomide and Radiotherapy in Ptients with Newly Diagnosed who Grade IV Malignant Glioma

Project: Research project

StatusActive
Effective start/end date9/25/179/25/20

Funding

  • Triphase Accelerator US Corp. (DRUG MRZ-112)
  • Celgene International II Sàrl (DRUG MRZ-112)